RedHill Biopharma Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-04-28 | — | — | — |
| 2022-11-29 | -10.00 | -60.00 | -500.00% |
| 2022-11-07 | -10.00 | -20.00 | -100.00% |
| 2022-06-23 | -30.00 | -30.00 | — |
| 2022-03-17 | -430.00 | -500.00 | -16.28% |
| 2021-11-30 | -282.00 | -50.00 | +82.27% |
| 2021-08-26 | -248.00 | -600.00 | -141.94% |
| 2021-05-27 | -278.00 | -500.00 | -79.86% |
| 2021-03-18 | -237.50 | -700.00 | -194.74% |
| 2020-11-12 | -185.00 | -499.82 | -170.17% |
| 2020-08-13 | -90.00 | -40.00 | +55.56% |
| 2020-05-27 | -600.00 | -500.00 | +16.67% |
| 2020-03-04 | -237.50 | -300.00 | -26.32% |
| 2019-11-19 | -292.50 | -300.00 | -2.56% |
| 2019-07-23 | -346.67 | -400.00 | -15.38% |
| 2019-05-07 | -346.67 | -300.00 | +13.46% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RDHL | -7.83% | +6.38% | -2.91% | -44.44% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -10.80% | +11.21% | +0.53% | -57.06% |